Prognostic markers in gliomas (Q37750781)

22 August 2017

1 reference

title

Prognostic markers in gliomas (English)

1 reference

22 August 2017

4

François Ducray

1 reference

22 August 2017

Marianne Labussiere

1

1 reference

22 August 2017

Xiao-Wei Wang

series ordinal

2

1 reference

22 August 2017

Ahmed Idbaih

series ordinal

3

1 reference

22 August 2017

Marc Sanson

series ordinal

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

733-739

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

22 August 2017

cites work

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Primary brain tumours in adults.

21 January 2018

1 reference

Advances in the genetics of glioblastoma: are we reaching critical mass?

21 January 2018

1 reference

Oligodendrogliomas: molecular biology and treatment.

21 January 2018

1 reference

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas

21 January 2018

1 reference

Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri

21 January 2018

1 reference

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

Dynamic history of low-grade gliomas before and after temozolomide treatment

21 January 2018

1 reference

Diagnostic and prognostic markers in gliomas

21 January 2018

1 reference

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

21 January 2018

1 reference

Two types of chromosome 1p losses with opposite significance in gliomas

21 January 2018

1 reference

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss

21 January 2018

1 reference

NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas

21 January 2018

1 reference

Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas

21 January 2018

1 reference

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

21 January 2018

1 reference

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study

21 January 2018

1 reference

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

21 January 2018

1 reference

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

alpha-Internexin expression identifies 1p19q codeleted gliomas.

21 January 2018

1 reference

Epigenetic mechanisms in glioblastoma multiforme

21 January 2018

1 reference

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

21 January 2018

1 reference

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

21 January 2018

1 reference

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

21 January 2018

1 reference

Mechanisms of disease: genetic predictors of response to treatment in brain tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.25

1 reference

22 August 2017

1 reference